Tag Archives: Stomach Cancer

Ramucirumab in stomach cancer: Added benefit not proven

Former orphan drug is undergoing regular early benefit assessment / studies submitted were unsuitable Ramucirumab (trade name: Cyramza) is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours. This aims to slow the growth of the tumours. As a so-called orphan drug, i.e. a drug for the treatment ...

Read More »